title: [Pharmacological properties of abiraterone acetate (ZYTIGA® tablet 250 mg), a new drug for the treatment of castration-resistant prostate cancer, and results of its clinical studies].
authors.forename: Michiko
authors.initials: M
authors.lastname: Iwata
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Tsutsumi
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Harada
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D013607:Tablets; D023041:Xenograft Model Antitumor Assays
chemical_list: D000736:Androstenes; D013607:Tablets; D000069501:Abiraterone Acetate